Related Experiment Video
Updated: Dec 28, 2025

Studying Cell Cycle-regulated Gene Expression by Two Complementary Cell Synchronization Protocols
Published on: June 6, 2017
The Cell Cycle Checkpoint System MAST(L)-ENSA/ARPP19-PP2A is Targeted by cAMP/PKA and cGMP/PKG in Anucleate Human
Elena J Kumm1, Oliver Pagel2, Stepan Gambaryan1,3
1Center for Thrombosis and Hemostasis (CTH), University Medical Center of the Johannes Gutenberg-University Mainz, 55131 Mainz, Germany.
Abstract:
The cell cycle is controlled by microtubule-associated serine/threonine kinase-like (MASTL), which phosphorylates the cAMP-regulated phosphoproteins 19 (ARPP19) at S62 and 19e/α-endosulfine (ENSA) at S67and converts them into protein phosphatase 2A (PP2A) inhibitors. Based on initial proteomic data, we hypothesized that the MASTL-ENSA/ARPP19-PP2A pathway, unknown until now in platelets, is regulated and functional in these anucleate cells. We detected ENSA, ARPP19 and various PP2A subunits (including seven different PP2A B-subunits) in proteomic studies of human platelets. ENSA-S109/ARPP19-S104 were efficiently phosphorylated in platelets treated with cAMP- (iloprost) and cGMP-elevating (NO donors/riociguat) agents. ENSA-S67/ARPP19-S62 phosphorylations increased following PP2A inhibition by okadaic acid (OA) in intact and lysed platelets indicating the presence of MASTL or a related protein kinase in human platelets. These data were validated with recombinant ENSA/ARPP19 and phospho-mutants using recombinant MASTL, protein kinase A and G. Both ARPP19 phosphorylation sites S62/S104 were dephosphorylated by platelet PP2A, but only S62-phosphorylated ARPP19 acted as PP2A inhibitor. Low-dose OA treatment of platelets caused PP2A inhibition, diminished thrombin-stimulated platelet aggregation and increased phosphorylation of distinct sites of VASP, Akt, p38 and ERK1/2 MAP kinases. In summary, our data establish the entire MASTL(like)-ENSA/ARPP19-PP2A pathway in human platelets and important interactions with the PKA, MAPK and PI3K/Akt systems.
Insights
The MASTL-ENSA/ARPP19-PP2A pathway regulates platelet function. This study identifies this cell cycle pathway in human platelets, impacting aggregation and kinase signaling.
Area of Science:
- Cell Biology
- Molecular Biology
- Hematology
Background:
- The cell cycle is regulated by MASTL kinase, which influences PP2A activity via ENSA/ARPP19.
- The MASTL-ENSA/ARPP19-PP2A pathway's role in platelets was previously unknown.
Purpose of the Study:
- To investigate the presence and function of the MASTL-ENSA/ARPP19-PP2A pathway in human platelets.
- To explore the pathway's interactions with other signaling systems in platelets.
Main Methods:
- Proteomic analysis of human platelets to detect pathway components.
- In vitro phosphorylation and dephosphorylation assays using recombinant proteins.
- Pharmacological inhibition of PP2A and assessment of platelet aggregation and kinase activity.
Main Results:
- ENSA, ARPP19, and PP2A subunits were identified in human platelets.
- Phosphorylation of ENSA/ARPP19 was observed upon cAMP/cGMP elevation and PP2A inhibition.
- PP2A inhibition reduced platelet aggregation and altered VASP, Akt, and MAPK phosphorylation.
Conclusions:
- The complete MASTL(like)-ENSA/ARPP19-PP2A signaling pathway is present and functional in human platelets.
- This pathway interacts with PKA, MAPK, and PI3K/Akt signaling systems.
- The pathway plays a role in regulating platelet aggregation and kinase signaling.
Related Concept Videos
The Cell Cycle Control System
Cyclins and cyclin-dependent kinases (Cdks) are the primary cell cycle regulators and...
The Cell Cycle Control System
M-Cdk Drives Transition Into Mitosis
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
DNA Damage can Stall the Cell Cycle
DNA Damage Can Stall the Cell Cycle
Inhibition of Cdk Activity

